{"id":"https://openalex.org/W4362525151","doi":"https://doi.org/10.1158/2643-3230.c.6550243","title":"Data from Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia","display_name":"Data from Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia","publication_year":2023,"publication_date":"2023-04-04","ids":{"openalex":"https://openalex.org/W4362525151","doi":"https://doi.org/10.1158/2643-3230.c.6550243"},"language":"en","primary_location":{"id":"doi:10.1158/2643-3230.c.6550243","doi":"https://doi.org/10.1158/2643-3230.c.6550243","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2643-3230.c.6550243","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/2643-3230.c.6550243","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5040303721","display_name":"Joshua F. Zeidner","orcid":"https://orcid.org/0000-0002-9014-1514","observed_orcids":["https://orcid.org/0000-0002-9014-1514"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Joshua F. Zeidner","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-9014-1514","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020894945","display_name":"Benjamin Garrett Vincent","orcid":"https://orcid.org/0000-0002-1762-2282","observed_orcids":["https://orcid.org/0000-0002-1762-2282"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Benjamin G. Vincent","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-1762-2282","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025478600","display_name":"Anastasia Ivanova","orcid":"https://orcid.org/0000-0003-4321-2073","observed_orcids":["https://orcid.org/0000-0003-4321-2073"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anastasia Ivanova","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5106628122","display_name":"Dominic T. Moore","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dominic Moore","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005855096","display_name":"Karen P. McKinnon","orcid":"https://orcid.org/0000-0002-1779-5626","observed_orcids":["https://orcid.org/0000-0002-1779-5626"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Karen P. McKinnon","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068251484","display_name":"Alec D. Wilkinson","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alec D. Wilkinson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001003479","display_name":"Rupkatha Mukhopadhyay","orcid":"https://orcid.org/0000-0002-4120-2966","observed_orcids":["https://orcid.org/0000-0002-4120-2966"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Rupkatha Mukhopadhyay","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014676751","display_name":"Francesco Mazziotta","orcid":"https://orcid.org/0000-0002-6126-8719","observed_orcids":["https://orcid.org/0000-0002-6126-8719"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Francesco Mazziotta","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042434251","display_name":"Hanna A. Knaus","orcid":"https://orcid.org/0000-0002-9715-5054","observed_orcids":["https://orcid.org/0000-0002-9715-5054"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hanna A. Knaus","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031561153","display_name":"Matthew Charles Foster","orcid":"https://orcid.org/0000-0002-6652-3838","observed_orcids":["https://orcid.org/0000-0002-6652-3838"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Matthew C. Foster","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-6652-3838","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017578509","display_name":"Catherine Callaghan Coombs","orcid":"https://orcid.org/0000-0001-5615-2247","observed_orcids":["https://orcid.org/0000-0001-5615-2247","https://orcid.org/0000-0003-4656-7304"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Catherine C. Coombs","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113893827","display_name":"Katarzyna Joanna Jamieson","orcid":"https://orcid.org/0009-0004-0947-0874","observed_orcids":["https://orcid.org/0009-0004-0947-0874"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Katarzyna Jamieson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103622451","display_name":"Hendrik Van Deventer","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hendrik Van Deventer","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068544225","display_name":"Jonathan Allen Webster","orcid":"https://orcid.org/0000-0003-3647-6345","observed_orcids":["https://orcid.org/0000-0003-3647-6345"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jonathan A. Webster","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069675791","display_name":"Gabrielle T. Prince","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gabrielle T. Prince","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035609080","display_name":"Amy Elizabeth Dezern","orcid":"https://orcid.org/0000-0001-5225-4609","observed_orcids":["https://orcid.org/0000-0001-5225-4609"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Amy E. DeZern","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012395020","display_name":"Bruce Douglas Smith","orcid":"https://orcid.org/0000-0002-0903-7390","observed_orcids":["https://orcid.org/0000-0002-0903-7390"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"B. Douglas Smith","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-0903-7390","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089694123","display_name":"Mark J. Levis","orcid":"https://orcid.org/0000-0003-0473-6982","observed_orcids":["https://orcid.org/0000-0003-0473-6982","https://orcid.org/0000-0003-4219-6315"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark J. Levis","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045281097","display_name":"Nathan D. Montgomery","orcid":"https://orcid.org/0000-0003-1765-6623","observed_orcids":["https://orcid.org/0000-0003-1765-6623"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nathan D. Montgomery","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014659694","display_name":"Leo Luznik","orcid":"https://orcid.org/0009-0005-7951-5190","observed_orcids":["https://orcid.org/0009-0005-7951-5190"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Leo Luznik","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026510629","display_name":"Jonathan Stuart Serody","orcid":"https://orcid.org/0000-0003-4568-1092","observed_orcids":["https://orcid.org/0000-0003-4568-1092"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jonathan S. Serody","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5046719320","display_name":"Ivana Gojo","orcid":"https://orcid.org/0000-0003-0312-3412","observed_orcids":["https://orcid.org/0000-0003-0312-3412"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ivana Gojo","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-0312-3412","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.7813000082969666,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.7813000082969666,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.21119999885559082,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9509999752044678},{"id":"https://openalex.org/keywords/high-dose-cytarabine","display_name":"high-dose cytarabine","score":0.8999999761581421},{"id":"https://openalex.org/keywords/relapsed-refractory-acute-myeloid-leukemia","display_name":"relapsed/refractory acute myeloid leukemia","score":0.9779999852180481},{"id":"https://openalex.org/keywords/anti-pd-1-therapy","display_name":"anti-PD-1 therapy","score":0.8939999938011169},{"id":"https://openalex.org/keywords/immune-checkpoint-blockade","display_name":"immune checkpoint blockade","score":0.8619999885559082},{"id":"https://openalex.org/keywords/t-cell-exhaustion","display_name":"T cell exhaustion","score":0.6370000243186951},{"id":"https://openalex.org/keywords/tcf1","display_name":"TCF1","score":0.7580000162124634},{"id":"https://openalex.org/keywords/cd8-t-cells","display_name":"CD8+ T cells","score":0.7950000166893005},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.8880000114440918},{"id":"https://openalex.org/keywords/maintenance-therapy","display_name":"maintenance therapy","score":0.5320000052452087},{"id":"https://openalex.org/keywords/immunophenotyping","display_name":"immunophenotyping","score":0.4790000021457672}],"concepts":[{"id":"https://openalex.org/C2778041864","wikidata":"https://www.wikidata.org/wiki/Q180983","display_name":"Cytarabine","level":3,"score":0.7085545659065247},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6868122816085815},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.6769067049026489},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.6163474321365356},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.606814980506897},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5229830741882324},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.48111337423324585},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.4809393286705017},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.43709713220596313},{"id":"https://openalex.org/C2780851360","wikidata":"https://www.wikidata.org/wiki/Q21686041","display_name":"Immune checkpoint","level":4,"score":0.4314461648464203},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.38818851113319397},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.37486380338668823},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.2930058538913727},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.11577928066253662},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.10055080056190491},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1158/2643-3230.c.6550243","doi":"https://doi.org/10.1158/2643-3230.c.6550243","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2643-3230.c.6550243","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"doi:10.1158/2643-3230.c.6550243.v1","doi":"https://doi.org/10.1158/2643-3230.c.6550243.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/2643-3230.c.6550243.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/2643-3230.c.6550243","doi":"https://doi.org/10.1158/2643-3230.c.6550243","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2643-3230.c.6550243","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320310145","display_name":"Johns Hopkins University","ror":"https://ror.org/00za53h95"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":43,"referenced_works":["https://openalex.org/W1569756545","https://openalex.org/W1805359866","https://openalex.org/W1982766090","https://openalex.org/W2040587086","https://openalex.org/W2044224425","https://openalex.org/W2053627244","https://openalex.org/W2053999133","https://openalex.org/W2064308486","https://openalex.org/W2089071559","https://openalex.org/W2095012072","https://openalex.org/W2095429270","https://openalex.org/W2097192169","https://openalex.org/W2107027906","https://openalex.org/W2109611268","https://openalex.org/W2116858301","https://openalex.org/W2150480709","https://openalex.org/W2159746057","https://openalex.org/W2196159484","https://openalex.org/W2419140434","https://openalex.org/W2522337762","https://openalex.org/W2618433578","https://openalex.org/W2623089849","https://openalex.org/W2899030939","https://openalex.org/W2899512090","https://openalex.org/W2900410545","https://openalex.org/W2903041954","https://openalex.org/W2908581980","https://openalex.org/W2909486828","https://openalex.org/W2913558101","https://openalex.org/W2938731144","https://openalex.org/W2952775948","https://openalex.org/W2965282989","https://openalex.org/W2994938720","https://openalex.org/W3014292375","https://openalex.org/W3030534638","https://openalex.org/W3034640151","https://openalex.org/W3046214598","https://openalex.org/W3085208365","https://openalex.org/W3092341078","https://openalex.org/W3093280293","https://openalex.org/W3112665570","https://openalex.org/W4246288707","https://openalex.org/W4249645487"],"related_works":["https://openalex.org/W3199415367","https://openalex.org/W2985626379","https://openalex.org/W2911080214","https://openalex.org/W2971698462","https://openalex.org/W4206900809","https://openalex.org/W3097947601","https://openalex.org/W4225795856","https://openalex.org/W3096647022","https://openalex.org/W3176711624","https://openalex.org/W3198085624"],"abstract_inverted_index":{"Abstract":[0],"Immune":[1],"suppression,":[2],"exhaustion,":[3],"and":[4,72,80,88,101,113,145,155,166,182,194],"senescence":[5],"are":[6],"frequently":[7],"seen":[8],"throughout":[9],"disease":[10],"progression":[11],"in":[12,43,131,171,179,204,219],"acute":[13],"myeloid":[14],"leukemia":[15],"(AML).":[16],"We":[17],"conducted":[18],"a":[19,120],"phase":[20],"II":[21],"study":[22,191],"of":[23,123,142,153,192],"high-dose":[24,169],"cytarabine":[25,170],"followed":[26],"by":[27,209],"pembrolizumab":[28,51,163,193],"200":[29],"mg":[30],"i.v.":[31],"on":[32,150],"day":[33],"14":[34],"to":[35,54,136,157],"examine":[36],"whether":[37],"PD-1":[38],"inhibition":[39],"improves":[40],"clinical":[41,176],"responses":[42],"relapsed/refractory":[44],"(R/R)":[45],"AML.":[46,205],"Overall":[47],"responders":[48],"could":[49],"receive":[50],"maintenance":[52],"up":[53],"2":[55],"years.":[56],"Among":[57],"37":[58],"patients":[59],"enrolled,":[60],"the":[61,132,220],"overall":[62,74],"response":[63,154],"rate,":[64],"composite":[65],"complete":[66],"remission":[67],"(CRc)":[68],"rate":[69],"(primary":[70],"endpoint),":[71],"median":[73],"survival":[75],"(OS)":[76],"were":[77,110],"46%,":[78],"38%,":[79],"11.1":[81],"months,":[82,103],"respectively.":[83],"Patients":[84,115],"with":[85,162,174],"refractory/early":[86],"relapse":[87],"those":[89,183],"receiving":[90,184],"treatment":[91,185],"as":[92,186],"first":[93,187],"salvage":[94,188],"had":[95,119],"encouraging":[96,175],"outcomes":[97],"(median":[98],"OS,":[99],"13.2":[100],"11.3":[102],"respectively).":[104],"Grade":[105],"\u22653":[106],"immune-related":[107],"adverse":[108],"events":[109],"rare":[111],"(14%)":[112],"self-limiting.":[114],"who":[116],"achieved":[117],"CRc":[118],"higher":[121],"frequency":[122],"progenitor":[124],"exhausted":[125],"CD8+":[126],"T":[127],"cells":[128],"expressing":[129],"TCF-1":[130],"bone":[133],"marrow":[134],"prior":[135],"treatment.":[137],"A":[138],"multifaceted":[139],"correlative":[140],"approach":[141],"genomic,":[143],"transcriptomic,":[144],"immunophenotypic":[146],"profiling":[147],"offers":[148],"insights":[149],"molecular":[151],"correlates":[152],"resistance":[156],"pembrolizumab.":[158],"Significance:":[159],"Immune-checkpoint":[160],"blockade":[161,197],"was":[164],"tolerable":[165],"feasible":[167],"after":[168,199],"R/R":[172],"AML,":[173],"activity,":[177],"particularly":[178],"refractory":[180],"AML":[181],"regimen.":[189],"Further":[190],"other":[195],"immune-checkpoint":[196],"strategies":[198],"cytotoxic":[200],"chemotherapy":[201],"is":[202,217],"warranted":[203],"See":[206],"related":[207],"commentary":[208],"Wei":[210],"et":[211],"al.,":[212],"p.":[213,225],"551.":[214],"This":[215,222],"article":[216],"highlighted":[218],"In":[221],"Issue":[223],"feature,":[224],"549":[226]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-04-06T00:00:00"}